With President Trump trying to bring API manufacturing back to The USA to help us rely less on China and India, hopefully all US drug manufacturers can all benefit from this move including Amneal.
Here is a good reason why Amneal is a great candidate for long term success.
https://investors.amneal.com/news/press-releases/press-release-details/2019/Amneal-to-Acquire-Majority-Interest-in-AvKARE-Enhancing-Access-to-Growing-Federal-Healthcare-Market/default.aspx
Here is a good reason why Amneal is a great candidate for long term success.
https://investors.amneal.com/news/press-releases/press-release-details/2019/Amneal-to-Acquire-Majority-Interest-in-AvKARE-Enhancing-Access-to-Growing-Federal-Healthcare-Market/default.aspx
Recent AMRX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/12/2026 08:10:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/11/2026 10:56:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 08:28:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 08:27:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 08:26:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 08:24:19 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 08:22:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:15:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:09:04 PM
- Amneal Reports First Quarter 2026 Financial Results • GlobeNewswire Inc. • 05/07/2026 08:01:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/27/2026 08:12:24 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2026 08:18:56 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/22/2026 09:00:19 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/22/2026 08:28:17 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/22/2026 08:26:18 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/22/2026 08:24:41 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/22/2026 08:23:25 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/22/2026 10:24:08 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/22/2026 10:22:26 AM
- Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader • Business Wire • 04/22/2026 10:17:00 AM
- Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance • GlobeNewswire Inc. • 04/22/2026 10:00:00 AM
- Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY® • GlobeNewswire Inc. • 04/20/2026 12:00:00 PM
- Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S. • GlobeNewswire Inc. • 04/14/2026 12:00:00 PM
- Amneal Launches Bimatoprost Ophthalmic Solution, 0.01% • GlobeNewswire Inc. • 04/09/2026 12:00:00 PM
- Amneal to Report First Quarter 2026 Results on May 1, 2026 • GlobeNewswire Inc. • 04/07/2026 08:01:00 PM
